Mechanistically, the MEK inhibitor increases BIM levels, while panobinostat acts as a de facto MCL-1 and BCL-xL inhibitor, dissociating BIM:MCL-1 and BIM:BCL-xL complexes in MM cells. This evidence concerns the gene BCL2L11 and Miyoshi myopathy.